Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency  by McGonigle, Richard J.S. et al.
Kidney International, Vol. 25 (1984), PP. 437—444
Erythropoietin deficiency and inhibition of erythropoiesis
in renal insufficiency
RICHARD J. S. MCGONIGLE, JOHN D. WALLIN, RICHARD K. SHADDUCK,
and JAMES W. FISHER
Departments of Pharmacology and Medicine, Tulane University School of Medicine, New Orleans, Louisiana, and Department
of Medicine, Montefiore Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Erythropoietin deficiency and inhibition of erythropoiesis in renal
insufficiency. The relative importance of erythropoietin (Ep) and inhibi-
tion of erythropoiesis in the anemia of chronic renal insufficiency has
been investigated. Sixty patients with varying degrees of renal insuffi-
ciency, 40 normal subjects and 40 patients with anemia and normal
renal function, were studied. Erythroid (CFU-E) and granulocytic
(CFU-GM) progenitor cell colony formation were assayed in fetal
mouse liver and human bone marrow cultures, respectively. Erythro-
poietin was measured by radioimmunoassay. Hematocrit and plasma
creatinine concentration correlated with the degree of serum inhibition
of CFU-E formation (r = 0.69, P < 0.001, and r = 0.62, P < 0.001,
respectively). Serum erythropoietin levels in patients with renal insuffi-
ciency (34.4 6.7mU/mi) were slightly higher than normal values (23.1
0.98 mU/mi), but showed no relationship to plasma creatinine,
hematocrit, or inhibition of CFU-E formation. In contrast, serum
erythropoietin concentrations increased exponentially as the hemato-
crit decreased below 32% (r = 0.61, P < 0.001), and CFU-E formation
was stimulated by serum in anemia patients with normal renal function.
Studies of granulopoiesis showed uremic sera supported in vitro CFU-
GM growth more efficiently than sera from normal subjects. These
results suggest that inhibition of erythroid, but not granulocytic,
progenitor cell formation, in addition to a relative erythropoietin
deficiency, are the primary factors responsible for the anemia of
chronic renal failure.
Deficit en érythropoietine et inhibition de t'érythropoièse au cours de
l'insuffisance rénale. L'importance relative de l'erythropoIétine (Ep) et
l'inhibition de l'drythropoIese lors de l'anémie de l'insuffisance rénale
chronique ont été étudiées. Soixante malades avec des degres variables
d'insuffisance rénale, 40 sujets normaux et 40 malades avec une anémie
et une fonction rénale normale, ont été étudiés. La formation de
colonies cellulaires souches érythroIde (CFU-E) et granulocytaire
(CFU-GM) ont été mesurées dans du foie foetal de souris et dans des
cultures de moelle osseuse humaine, respectivement. L'érythropoIétine
a été mesurée par dosage radioimmunologique. L'hématocrite et Ia
concentration plasmatique de créatinine étaient corrélées avec le degré
d'inhibition sérique de Ia formation de CFU-E (r = 0,69, P < 0,001; et r
= 0,62, P < 0,001, respectivement). Les niveaux d'drythropoIétine
serique chez les malades atteints d'insuffisance rénale (34,4 6,7
mU/ml) étaient légerement plus élevés que les valeurs normales (23,1
0,98 mU/mI), mais 11 n'y avait pas de relation avec Ia créatininémie,
l'hématocrite, ou l'inhibition de formation de CFU-E. A l'oppose, les
concentrations d 'érythropoIétine sérique s 'élevaient exponentiellement
au fur et a mesure que l'hématocrite diminuait en dessous de 32% (r =
0,61, P <0,001), et Ia formation de CFU-E était stimulée par du serum
chez des malades anémiques avec une fonction rCnale normale. Des
etudes de Ia granulopoIese ont montré que les serums urémiques
supportaient Ia croissance in vitro de CFU-GM de facon plus efficace
que les serums de sujets normaux. Ces résultats suggerent que l'inhibi-
tion de formation de cellules souches érythroIdes et non granulocy-
taires, en plus d'un relatif deficit en erythropoIétine, sont les facteurs
primaires responsables de l'anémie de l'insuffisance rénale chronique.
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Patients with chronic renal failure invariably suffer from a
normocytic normochromic anemia associated with a hypopro-
liferative bone marrow. The primary site of production of
erythropoietin is the kidney although serum erythropoietin is
detectable in surgically anephric patients. In these cases extra-
renal erythropoietin is most probably produced in the liver.
Inadequate erythropoietin production to sustain erythropoiesis
has been considered as the primary etiologic factor in the
anemia of renal disease. However, erythropoietin levels have
been reported to be elevated, normal, and decreased in the
serum of renal failure patients [1—4]. The relatively insensitive
bioassay systems for serum erythropoietin are subject to con-
siderable variability. The in vivo bioassay in polycythemic mice
requires the concentration of large quantities of serum to detect
normal levels; the various in vitro bioassays may be affected by
inhibitors or stimulators of erythropoiesis also present in the
serum. The radioimmunoassay for erythropoietin used in the
present study has been validated [5], showing a high degree of
correlation with the polycythemic mouse bioassay.
It seems probable that the deficiency of erythropoietin is
relative to the increased demands made on the kidney in the
uremic state created by shortened red cell life span [6], in-
creased blood loss from various sources, and inhibition of
erythropoiesis by the accumulation of retained uremic toxins
[7]. These inhibitors of erythropoiesis include substances that
effect both the progenitor cell compartments (CFU-E, colony-
forming unit-erythroid; BFU-E, burst-forming unit-erythroid)
[8—10] and heme synthesis [11—12]. It is possible that the
decrease in heme synthesis is secondary and merely reflects
inhibition of the more primitive erythropoietin responsive cell
compartment. Inhibition of marrow thymidine incorporation by
sera from patients with uremia has also been reported [13].
The identification of potential inhibitors of erythropoiesis has
not been fully established. Urea, creatinine, and guanidinosuc-
cinic acid are all potential inhibitors that are elevated in uremic
sera, however, these compounds are not inhibitory to heme
synthesis or CFU-E growth [8, 11] in the concentration range
seen in renal failure. In vitro effects of PTH on erythroid
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progenitor cells vary considerably; both stimulatory and inhibi-
tory effects have been reported [14—16]. The association be-
tween hyperparathyroidism and anemia in renal failure patients
may be related to bone marrow fibrosis [17]. The polyamine,
spermine, inhibits CFU-E formation in both fetal mouse liver
and human bone marrow cultures at concentrations similar to
that found in uremic serum [91. In addition, an antibody to
spermine was found to remove the inhibitory effect of uremic
serum on erythroid progenitor cells [91.
In the present study we have examined the effect of several
factors on erythropoiesis in patients with varying degrees of
impaired renal function. Firstly, serum erythropoietin levels
were measured in renal failure patients and compared to those
from patients with similar degrees of anemia with normal renal
function. Secondly, serum inhibitors were measured by the
CFU-E technique and were correlated with the degree of
suppression of erythropoiesis.
Methods
Patients
(1) Sixty patients with varying degrees of renal insufficiency
from the Tulane Medical Center Hospital, Veterans Adminis-
tration Hospital, and Charity Hospital of New Orleans were
studied after informed consent had been obtained. Their ages
ranged from 17 to 94 years (mean SEM, 54 2.0 years).
Eighteen patients were female and 42 male. No patient had
received any form of dialysis prior to the study. The majority of
patients were receiving oral vitamin supplementation. No pa-
tient was receiving oral androgen therapy. The etiology of renal
disease covered a wide spectrum of diseases including hyper-
tension, 19 patients; diabetes mellitus, 9; glomerulonephritis,
12; polycystic kidney disease, 3; obstructive uropathy, 4;
chronic pyelonephritis, 4; analgesic nephropathy, 1; Alport
syndrome, 2; multiple myeloma, 1; gout uropathy, 1; congenital
dysplasia, 1; unknown, 3. Four patients had evidence indicating
other possible causes of their anemia apart from renal disease:
Two patients had active peptic ulceration confirmed by endos-
copy, one suffered from sickle cell anemia, and one patient had
multiple myeloma.
(2) Forty normal subjects were selected from volunteer blood
donors at the Ochsner Clinic, New Orleans, Louisiana. The
ages of these subjects ranged from 23 to 63 years (mean 5EM,
41 2 years) and consisted of 12 females and 28 males.
Hemoglobin concentrations ranged from 13.3 to 17.4 g/dl (mean
SEM, 15.7 0.17 g/dl). Two patients were receiving thiazide
diuretic treatment for mild hypertension, and one patient was
administered thyroid replacement therapy. All patients had
normal renal function as measured by serum creatinine
concentration.
(3) Twenty-seven female and 13 male patients were studied
with varying degrees of anemia. These patients were attending
the Hematology Clinic, Charity Hospital in New Orleans. All
had normal renal function as measured by urinalysis and serum
creatinine. Hematocrit levels ranged from 17.8 to 52.0%. Most
of the patients were anemic with sickle cell anemia, 11; chronic
gastrointestinal bleeding, 2; iron deficiency anemia, 8; thalasse-
mia, 3; vitamin 12 deficiency, 4; folate deficiency, 1; methyl-
dopa induced hemolysis, 1; aplastic anemia, 2; idiopathic
thrombocytopenic purpura, 3; and polycythemia vera, 3. Their
Table 1. Effect of normal and uremic serum on granulocytic
colony growth°
Experiment Control
Normal
serum
Uremic
serum
1 86.6 8.1 77.9 4.7(N=8) 96.1
34b
(N=l4)
2 160.0 5.8 110.9 3.1
(N=9)
135.6 3.7"
(N=30)
3 70.7 3.9 48.4 2.3
(N=9)
38.7 4.0°
(N=15)
The values represent the number of colonies/2 X iO human marrow
cells; numbers are means SEM.
"The value is significantly (P < 0.01) higher than in normal subjects.
The value is significantly (P < 0.05) less than in normal subjects.
ages ranged from 15 to 81 years (mean sEM, 41.8 3.2 years).
After informed consent, 25 ml of blood were drawn from each
patient and centrifuged. The serum was stored at —70°C in
respective aliquots until the various assays were performed.
Investigations
Radioimmunoassay for serum erythropoietin [51. Highly puri-
fied erythropoietin (70,400 U/mg protein) obtained from the
National Heart, Lung and Blood Institute, Bethesda, Maryland,
and prepared by Dr. Eugene Goidwasser's laboratory at the
University of Chicago was labelled with iodine-125 by the
chloramine T method of Greenwood and Hunter [18]. Erythro-
poietin antiserum was prepared in rabbits. A human urinary
erythropoietin preparation with a specific activity of 80 U/mg
protein obtained from the National Heart, Lung and Blood
Institute' was used for the immunization. The antiserum was
absorbed with normal human serum and urinary proteins to
increase the specificity of the assay for erythropoietin. A
second antibody (goat antirabbit gamma globulin) was used for
the separation of bound from free labelled antigen.
Fetal mouse liver cell culture technique. Liver cells from 12
to 14-day-old fetuses of CD-i mice were prepared according to
the technique of Iscove, Sieber, and Winterhalter [19]. Liver
cells were disaggregated and suspended as single cells at a
concentration of i05 cells/mi in a culture medium containing
alpha modified Eagle's medium with Earle's salts without
ribosides and deoxyribosides and without glutamine, in methyl-
cellulose, 30% fetal calf serum, 100 mU of human urinary
erythropoietin', 0.1 M mercaptoethanol, 100 mU of penicillin,
and 100 tg of streptomycin. Human serum samples were heat-
inactivated at 56°C for 30 mm and sterile-filtered before being
tested at concentrations of 5, 10, and 20%; the amount of fetal
calf serum was altered accordingly to maintain a total serum
concentration of 30%.
Cell culture (1 ml) was plated in 35 x 10 mm petri dishes and
incubated for 48 hr at 37°C in a humidified atmosphere at 95%
air and 5% CO2. The pH was maintained constant as indicated
by the color of the phenol red indicator present in the Eagle's
'Human urinary erythropoietin was supplied by the Department of
Physiology, University of Northeast, Corrientes, Argentina. The mate-
rial was further processed and assayed by the Hematology Research
Laboratories, Children's Hospital of Los Angeles, under United States
Public Health Service research grant HE-10880 (National Heart, Lung
and Blood Institute).
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Fig. 1. Relationship between hematocrit and plasma creatinine concen-
tration in 60 patients with varying degrees of renal insufficiency.
medium. After the plates were stained with diaminobenzidine
according to the method of Ogawa et a! [20], CFU-E of eight or
more cells were counted in four replicate plates using an
inverted microscope. One sixteenth of the plate area was
counted and considered representative of the total plate area
since very large numbers of colonies were present (1000 to 5000
colonies/plate). Only one batch of fetal calf serum (Flow
Laboratories 29101607) and one batch of erythropoietin (sp act
10 U/mg protein) were used to minimize variations in erythroid
colony formation. Human serum from one subject was used as a
standard control. CFU-E formation was expressed as a percent-
age of the control.
Human bone marrow culture for granulocytic colony forma-
tion. The effect of serum on in vitro granulocytic progenitor
cells was evaluated using an in vitro granulocyte colony-
forming technique [21]. Following informed consent, bone
marrow was aspirated from the posterior iliac crest from normal
volunteers into heparinized syringes. After sedimentation at
room temperature, the buffy coat was aspirated and washed
twice in modified McCoy's medium. Each culture was prepared
such that 2 x l0 marrow cells were immobilized in 1 ml of
supplemented McCoy's medium containing 15% fetal calf se-
rum in 0.3% agar. Cultures were plated in 10 x 35 mm tissue
culture petri dishes (Corning stock #25000, Corning, New
York). Five percent human fibroblast conditioned medium
served as a source of colony-stimulating factor (CSF) [22].
Serum inhibitor activity was assessed by the addition of 10%
normal serum or uremic serum to the cultures prior to the
addition of the agar-cell mixture. Cultures were allowed to gel
for 20 mm and subsequently incubated in a well humidified
7.5% CO2, 37°C atmosphere for 7 days. Colonies of more than
50 cells each were counted with the aid of a dissecting micro-
scope [23]. Five cultures were prepared for each sample; values
are expressed as means 1 SEM.
Serum CSF activity was measured using 2 x iø non-glass
adherent human bone cells [24]. This measure was used to
remove endogenous CSF-producing cells from the marrow
thereby eliminating spontaneous colony formation. Serum CSF
was assessed by addition of 10% patient or control sera to the
agar cultures.
Statistical analysis. Student's t test and linear regression
analysis were used for statistical comparisons.
Results
In patients with impaired renal function the serum creatinine
concentration ranged from 1.6 to 10.9 mg% and the hematocrit
from 16.5 to 52%. The severity of anemia was found to be
related inversely to the degree of impaired renal function as
indicated by the hematocrit and serum creatinine concentration
(r 0.677, P < 0.001; Fig. 1). However, a wide scatter of
hematocrit values was seen for the same level of renal function
reflecting the multiple causes of renal failure and their numer-
ous complications. In four patients subsequent investigations
showed other causes for their anemia in addition to renal
disease. One patient had sickle cell anemia, another patient had
multiple myeloma, and two patients had active peptic ulcer
disease. Figures 2 and 3 show the relationship between both
hematocrit and serum creatinine concentration, and the degree
of inhibition of erythroid progenitor cell (CFU-E) formation by
uremic sera at a concentration of 5% in cell culture (r =0.72, P
<0.001; and r =
—0.63, P <0.001, respectively). The lower the
hematocrit and the higher the serum creatinine concentration,
the greater the degree of inhibition of CFU-E formation. The
four patients with additional causes for their anemia showed
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Plasma creatinine, mg%
Fig. 3. Relationship between plasma creatinine concentration and
inhibition of erythroid colony formation in patients with renal insuffi-
ciency. The concentration of patient's serum in culture is 5%.
less inhibition of CFU-E formation than would be expected for
the degree of anemia due to renal disease. CFU-E inhibition
correlated with the plasma urea concentration in addition to the
serum creatinine concentration. This association was signifi-
cant in 5, 10, and 20% concentrations of uremic serum in fetal
mouse liver cell cultures. Sera from the 60 patients with renal
disease progressively reduced the growth of CFU-E from 83.5
2.0% (mean SEM) to 68.5 3.7% (P < 0.05) as the
concentration of uremic serum in culture was increased from 5
to 20% (Fig. 4). This contrasted significantly (P < 0.001) from
the 40 normal subjects studied whose serum did not demon-
strate significant stimulation or inhibition of CFU-E formation
at 5, 10, or 20% concentrations in culture.
The serum erythropoietin concentration in the renal failure
patients did not correlate with the plasma creatinine concentra-
tion (Fig. 5), hematocrit (Fig. 6), or the degree of inhibition of
erythroid colony formation (Fig. 7). Mean serum erythropoietin
levels were elevated above the normal range in the 60 patients
with renal disease although the difference between 34.67 6.7
(mean SEM) and 23.1 0.98 mU/mi was not significant and is
mostly due to the elevation above normal values in seven
patients and a marked elevation in serum erythropoietin con-
centrations in three patients. No specific cause for these
markedly elevated levels of erythropoietin could be found in
these three patients whose renal failure was due to focal
segmental glomerulonephritis secondary to heroin addiction,
hypertensive nephrosclerosis, and chronic glomerulonephritis.
In the 40 patients with hematologic disorders and normal
renal function the serum erythropoietin concentration increased
exponentially from 20 to 320 mU/mi with the decline in hemato-
crit from 52.0% to 17.8% (r =
—0.61, P < 0.001) (Fig. 8).
However, the increase in serum erythropoietin in response to
anemia was not seen until the hematocrit decreased below a
level of 32%. Furthermore, serum erythropoietin levels showed
a significant positive correlation with stimulation of CFU-E
formation (r = 0.54, P < 0.01) in the patients with anemia and
normal renal function (Fig. 9). Anemic patients with normal
renal function showed increasing stimulation of CFU-E forma-
tion with decreasing hematocrit values (r = —0.73, P < 0.001),
which was the opposite to that found in patients with anemia
and renal disease (Fig. 10). Three patients had a diagnosis of
polycythemia vera. Their hematocrit ranged from 40.1 to 52%
and their serum erythropoietin levels ranged from 23.6 to 41.2
mU/mi.
Studies of the effects of sera from patients with renal insuffi-
ciency on granulopoiesis in normal human bone marrow cul-
tures were performed in three separate experiments. Consider-
able variation in baseline control granulocyte colony (CFU-
GM) formation was seen between different experimental
groups. Sera from normal human subjects inhibited CFU-GM
formation in comparison to controls. In two of our experiments
the degree of inhibition of CFU-GM formation was less in
patients with renal insufficiency than in normal subjects. In the
third experiment the sera from patients with renal insufficiency
produced a greater degree of inhibition of CFU-GM formation
than did normal sera. However, of the 15 sera evaluated in the
third experiment, four were markedly inhibitory thereby affect-
ing the mean. The overall inhibition of CFU-GM formation by
sera from 26 normal subjects was significantly higher (P < 0.05)
than that of the 59 patients with renal insufficiency. No correla-
tion was seen between CFU-GM formation in patients with
renal insufficiency and hematocrit, plasma creatinine concen-
tration, of CFU-E formation. In a further study, no colony-
stimulating activity (CSA) was detectable in the sera from 15
patients with renal insufficiency or sera from nine normal
subjects.
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Discussion
Anemia of varying severity is a frequent complication in
patients suffering from chronic renal failure. Available evidence
suggests that two factors play a major role in the pathogenesis
of this anemia. The first factor and probably the most important
is a failure to produce sufficient quantities of erythropoietin to
correct the anemia and the second is the presence of uremic
toxins retained in the serum of patients with renal disease which
inhibit erythropoiesis. Inhibition of erythropoiesis has been
detected with sera from uremic patients in a number of different
tissue culture systems employing both human and animal bone
marrow cells and also in fetal mouse liver cultures. The
mechanism of this inhibition is not fully understood but appears
to be due to interference with the formation and subsequent
proliferation of the erythroid-committed progenitor cell com-
partment. Several investigators have reported that uremic se-
rum inhibits CFU-E and BFU-E formation, and heme synthesis
[8, 12]. In addition to these two factors, abnormal bleeding from
the uremic gut and shortened red cell life span [6] play a
variable role in the anemia of renal disease; circulating red cells
in uremia are often distorted in both shape and size, but
hemolysis is usually mild or absent until the later stages of
endstage renal disease. Guanidine derivatives, including meth-
ylguanidine, have been implicated in the etiology of this hemo-
lysis [25].
A wide variety of procedures have been utilized to assay
erythropoietin including the exhypoxic polycythemic mouse
bioassay and fetal mouse liver cell assay. The polycythemic
mouse assay is generally accepted as the international standard
assay for erythropoietin. However, these biological assays for
erythropoietin are hampered by their low level of sensitivity
and the possible interference by other inhibitory and stimula-
30 40 50
tory substances present in the uremic serum. Early studies
showed that the serum erythropoietin concentrations as mea-
sured by the polycythemic mouse bioassay were rarely elevated
in uremic patients. Erythropoietin has now been purified to
homogeneity [26] thereby providing purified hormone for use in
a radioimmunoassay which is both specific and highly sensitive
[5, 27—30]. Lange, Chen, and Dunn [31] summarized several
studies of in vitro and in vivo assays for erythropoietin and
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Fig. 8. Effect of decreasing hematocrit levels on serum erythropoietin
concentration in 40 patients with varying degrees of anemia and normal
renal function.
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Fig. 9. Relationship between serum etythropoietin concentration and
stimulation of erythroid colony formation in patients with varying
degrees of anemia and normal renal function. The concentration of
patient's serum in culture is 5%.
estimated normal human serum levels to be approximately 30
10 mU/ml varying with the method of assay used. Reports of
serum erythropoietin values measured by a radioimmunoassay
in renal failure patients [5, 28, 30] have only included small
numbers of patients. Normal levels of erythropoietin using the
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Fig. 10. Inverse relationship between stimulation of erythroid colony
formation and decreasing hematocrit levels in 40 patients with varying
degrees of anemia and normal renal function. The concentration of
patient's serum in culture is 5%.
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• radioimmunoassay range between 14.9 and 29.0 mU/mi [5, 27—
30]. Although most investigators have reported elevated serum
erythropoietin levels utilizing various assays in patients with
anemia and renal insufficiency, a recent investigation by De-
Kierk et al [32] using a fetal mouse liver cell bioassay for
erythropoietin reported reduced serum erythropoietin concen-
trations in uremic predialysis patients in comparison to normal
• subjects. It has been suggested that a sustained regulatory
feedback mechanism between hematocrit and serum erythro-
poietin persists in patients with renal failure but is at a tower
basal level [4]. Positive correlations of hemoglobin or hemato-
crit with serum erythropoietin measured by various bioassays
[4, 32] in uremic patients may represent an association between
236.99 anemia and inhibitors of erythropoiesis rather than with the
serum erythropoietin concentration.
In this study we have utilized an erythropoietin radio-
immunoassay and the fetal mouse liver cell culture system to
compare the relative roles of erythropoietin deficiency and
inhibitors of erythropoiesis in the development of anemia in a
large number of nondialyzed patients with varying degrees of
renal insufficiency and compared the results with anemic pa-
tients with normal function. Serum erythropoietin levels were
only elevated in seven of the 60 patients with renal insufficien-
cy. The presence of elevated serum erythropoietin levels in
uremic patients with anemia in other studies has prompted the
question of the exact role of erythropoietin deficiency in the
pathogenesis of the anemia of chronic renal failure. Our obser-
vations indicate that as renal function deteriorates and anemia
develops, the serum erythropoietin concentration remains un-
changed. In contrast, in anemic patients with normal renal
function there was an exponential increase in serum erythropoi-
etin concentration associated with increasing severity of the
anemia. The reponse of increased erythropoietin production to
anemia occurred only when the hematocrit declined below 32%.
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This inverse relationship between serum erythropoietin and
hematocrit in anemic patients with normal renal function sup-
ports the findings of other investigators using different assays
for erythropoietin [33, 34]. Thus, although serum erythropoietin
levels were slightly elevated above the normal range in patients
with renal failure, the titers were not sufficiently increased to
correct the anemia and therefore reflect a relative deficiency of
erythropoietin in comparison to patients with anemia and
normal renal function.
It was the degree of serum inhibition of CFU-E formation
rather than the serum erythropoietin concentration which cor-
related with both the degree of anemia and level of renal
function. This contrasted with the stimulation of CFU-E forma-
tion by serum from patients with anemia of similar severity and
normal renal function. Wallner and Vautrin [35] used two
different in vitro culture systems (heme synthesis in rabbit
erythroblasts and erythroid colony formation in mouse marrow
cells) to study inhibition of erythropoiesis by serum from
uremic patients. They found that the levels of inhibitor in-
creased as renal failure worsened and hematocrit fell. The
severity of anemia for the same level of renal function varied
widely in the patients included in our study. Similarly, the
degree of inhibition of erythroid colony formation also showed
a wide scatter for both the serum creatinine and hematocrit.
The variation in CFU-E inhibition for the same degree of
anemia may be explained, at least in part, by other causes of
anemia in addition to renal failure. Four such cases were
identified in our group of patients in which blood loss or
hemolysis was present, both of which would tend to increase
erythropoietin production and stimulate rather than inhibit
CFU-E formation.
The uremic inhibitors responsible for the suppression of
erythropoiesis appear to be specific for the erythroid progenitor
cell compartment (CFU-E, BFU-E) since only minimal effects
were noted on granulocytic colony formation. Indeed CFU-GM
formation in the presence of colony-stimulating activity (CSA)
was enhanced in two of three studies by uremic serum as
compared to normal control serum. The explanation for this
phenomenon is unclear; effects on CFU-GM formation did not
correlate with the white cell count, hematocrit, or level of renal
function. Vincent et al [36] similarly reported an absence of
inhibitory effect of uremic serum on CFU-GM formation when
preformed CSA was added in vitro, although inhibition of CSA
production by leucocytes in human marrow in vitro was seen.
The possibility must be considered that uremic serum lacks a
stimulator or a factor which supports growth of erythroid
progenitor cells (CFU-E) rather than containing an inhibitor of
erythropoiesis. The possibility was also considered that the
growth factor(s) in fetal calf serum, not present in human sera,
is diluted by the reciprocal dilution of fetal calf serum in our
system. However, increasing concentrations of normal adult
human sera and decreasing concentrations of fetal calf serum
did not produce a significant change in CFU-E in our fetal
mouse liver cultures (Fig. 4). Earlier work [91 demonstrating
that an antibody to spermine removed the inhibitory effects of
uremic serum on erythroid colony formation and the demon-
stration that spermine itself is an inhibitor of CFU-E is the best
support for a role of inhibitors rather than the lack of a
stimulator of erythropoiesis in the mechanism of the anemia of
uremia. However, until further work is carried out to purify the
uremic toxin(s) which might be responsible for the suppression
of erythropoiesis, this question cannot be completely resolved.
In conclusion, we have shown that the degree of inhibition of
erythroid colony formation by uremic serum correlates closely
with the level of renal function and the severity of anemia. The
presence of normal or slightly elevated serum erythropoietin
levels indicates a relative erythropoietin deficiency and reflects
an inadequate erythropoietin response for the degree of anemia.
Thus, it is the degree of inhibition of erythropoiesis which
appears to determine the severity of anemia in patients with
renal disease who have not yet started dialysis treatment.
Furthermore, the uremic toxins or inhibitors responsible for
inhibition of erythropoiesis appear to be specific for the ery-
throid progenitor cells.
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